Plaçais L, Kolanska K, Ben Kraiem Y, et al. - Researchers here examined the efficacy and safety of intralipid therapy to obtain a live birth among women with unexplained recurrent implantation failure (RIF) and miscarriage (RM). In this retrospective cohort study of 187 women treated for unexplained recurrent miscarriages and implantation failures, intralipid therapy was received by 26 women with median age of 36 years (29-43). Live births were reported in 7 (70%) pregnancies under intralipids; these were significantly more frequent than in women with recurrent miscarriages who did not receive intralipid therapy. Outcomes suggest that in women with unexplained recurrent miscarriages and infertility, intralipids could be an effective and safe therapy.